首页> 外文期刊>Journal of the American College of Cardiology >Strategies of clopidogrel load and atorvastatin reload to prevent ischemic cerebral events in patients undergoing protected carotid stenting: Results of the randomized ARMYDA-9 CAROTID (clopidogrel and atorvastatin treatment during carotid artery stenting) study
【24h】

Strategies of clopidogrel load and atorvastatin reload to prevent ischemic cerebral events in patients undergoing protected carotid stenting: Results of the randomized ARMYDA-9 CAROTID (clopidogrel and atorvastatin treatment during carotid artery stenting) study

机译:接受保护性颈动脉支架置入术的患者使用氯吡格雷负荷量和阿托伐他汀再负荷的策略以预防缺血性脑事件:ARMYDA-9 CAROTID的随机结果(在颈动脉支架置入术中使用氯吡格雷和阿托伐他汀治疗)研究

获取原文
获取原文并翻译 | 示例
           

摘要

Objectives: This study sought to evaluate whether a strategy with a 600-mg clopidogrel load and a short-term, high-dose atorvastatin reload would improve outcomes in clopidogrel-na?ve, statin-treated patients undergoing protected carotid stenting. Background: Optimal clopidogrel loading dose during carotid stenting has not been investigated; in addition, statin neuroprotection in this setting has not been described. Methods: A total of 156 patients were randomized using a 2 × 2 factorial design to receive either a 600-mg (n = 78) or 300-mg (n = 78) clopidogrel load given 6 h before intervention and either a atorvastatin reload (n = 76; 80 mg + 40 mg initiating 12 h before the procedure) or no statin reload (n = 80). The primary endpoint was the 30-day incidence of transient ischemic attack/stroke or new ischemic lesions on cerebral diffusion-weighted magnetic resonance imaging performed at 24 to 48 h. Results: Occurrence of the primary outcome measure was significantly lower in the 600-mg clopidogrel arm (18% vs. 35.9% in the 300-mg group; p = 0.019) and in the atorvastatin reload arm (18.4% vs. 35.0% in the no statin reload group; p = 0.031). High-dose clopidogrel also significantly reduced the transient ischemic attack/stroke rate at 30 days (0% vs. 9%, p = 0.02, secondary endpoint), without an increase in bleeding risk. Conclusions: In patients undergoing carotid stenting, a strategy using both a 600-mg clopidogrel load and a short-term reload with high-dose atorvastatin protects against early ischemic cerebral events. These results, obtained along with routine mechanical neuroprotection, provide new evidence of the optimization of drug therapy before percutaneous carotid intervention. (Clopidogrel and Atorvastatin Treatment During Carotid Artery Stenting [ARMYDA-9 CAROTID]; NCT01572623)
机译:目的:本研究旨在评估采用600毫克氯吡格雷负荷和短期大剂量阿托伐他汀再负荷的策略是否会改善接受保护性颈动脉支架置入的初次接受他汀类药物治疗的初次接受氯吡格雷的患者的结局。背景:尚未研究在颈动脉支架置入术期间最佳氯吡格雷负荷剂量;此外,他汀类药物在这种情况下的神经保护作用尚未描述。方法:采用2×2因子设计将156名患者随机分为两组,分别在干预前6小时接受600 mg(n = 78)或300 mg(n = 78)的氯吡格雷负荷和阿托伐他汀再负荷( n = 76;在手术前12小时开始服用80 mg + 40 mg)或没有他汀类药物补充(n = 80)。主要终点是在24至48小时进行的脑弥散加权磁共振成像在30天内发生的短暂性脑缺血发作/中风或新的缺血性病变。结果:主要结果指标的发生率在600毫克氯吡格雷组中显着降低(18%比300毫克组中35.9%; p = 0.019)和阿托伐他汀再装组中(18.4%对35.0%)。没有他汀类药物再加载组; p = 0.031)。大剂量氯吡格雷还可以显着降低30天时的短暂性脑缺血发作/中风发生率(0%比9%,p = 0.02,次要终点),而不会增加出血风险。结论:在接受颈动脉支架置入术的患者中,同时使用600毫克氯吡格雷负荷和短期再负荷大剂量阿托伐他汀的策略可预防早期缺血性脑事件。这些结果与常规的机械神经保护一起获得,为经皮颈动脉介入治疗之前药物治疗的优化提供了新的证据。 (在颈动脉支架置入术[ARMYDA-9 CAROTID]中使用氯吡格雷和阿托伐他汀治疗; NCT01572623)

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号